As;Modelos in vitro para el estudio de la lesion neuronal y de fârmacos potencialmente neuroprotectores

Revista de Neurologia

Volumn 25, Issue 148, 1997, Pages 2015-2021

  Abad Santos, F ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Celiitar death; Ischaemia in vitro models; Neuronal cultures; Newotoxicity; Pharmacologie newoprotection

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CITICOLINE; GLUTAMATE RECEPTOR ANTAGONIST; NEUROPROTECTIVE AGENT; SCAVENGER;

ANIMAL CELL; BRAIN PROTECTION; CELL CULTURE; CELL MEMBRANE; DRUG EFFECT; DRUG SCREENING; NERVE LESION; NEUROTOXICITY; NONHUMAN; REVIEW;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CALCIUM CHANNEL BLOCKERS; CELL DEATH; CELL MEMBRANE; CELLS, CULTURED; EXCITATORY AMINO ACID ANTAGONISTS; FREE RADICAL SCAVENGERS; MODELS, BIOLOGICAL; NEURONS; NEUROPROTECTIVE AGENTS;

EID: 0031430942     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Grisham JW, Smith GJ. Predictive and mechanistic evaluation of toxic responses in mammalian cell culture systems. Pharmacol Rev 1984; 36: SI51-71.
2. Roberfroid M, Goethals F. In vitro toxico-pharmacology: Past, present and future. In Castell JV, Gômez-Lechôn MJ, eds. In vitro alternatives to animal pharmaco-toxicology. Madrid: Farmaindustria; 1992. p. 17-41.
3. Rowan AN, Goldberg JA. Perspectives on alternatives to current animal testing techniques in preclinical toxicology. Ann Rev Pharmacol Toxicol 1985; 25: 225-47.
4. Schiinder R. Use of cell culture in pharmacology. Ann Rev Pharmacol 1969; 9: 393-406.
5. Abad Santos F. Citotoxicidad por 6-hidroxidopamina en células cromafines bovinas: mecanismo de acciôn y bùsqueda de fânnacos citoprotectores. Tesis Doctoral. Universidad Autönoma de Madrid, Facultad de Medicina, 1994.
6. Gômez-Lechôn MJ, Ponsoda X, Jover R, Donato T, Larrauri A, Castell JV. Hepatocitos humanos en cultivo: un modelo para la predicciôn de rieseo potencial de hepatotoxicidad de medicamentos. Rev Toxicol 1990; 7: 241-8.
7. Tardiff RG. In vitro methods of toxicity evaluation. Ann Rev Pharmacol Toxicol 1978; 18: 357-69.
8. Castell JV, Donato T, Larrauri A, Fabra R, Trullenque R, Gomez-Lechön MJ. Uso de hepatocitos humanos en cultivo para la predicciôn del riesiio potencial de hepatotoxicidad de medicamentos. Gastroenterol Hepatol 1989; 12: 483-95.
9. Purchase IFH, Longstaff E, Ashby J, et al. Evaluation of six short term tests for detecting organic chemical carcinogens and recommendations for their use. Nature 1976; 264: 624-7.
10. Rees KR. Cells in culture in toxicity testing: A review. J Royal Soc Med 1980; 73: 261-4.
11. Krieglstein J, Brungs H, Péniche B. Cultured neurons for testing of cerebroprotective drug effects in vitro. J Pharmacol Meth 1988; 20: 39-46.
12. Zapater Hemândez P. Estudio del modelo citoprotector de los fârmacos calcioantagonistas en el modelo de isquemia cerebral global en el jerbo y en el modelo de citotoxicidad por veratridina en células cromafines bovinas. Tesis Doctoral. Universidad Autönoma de Madrid, Facultad de Medicina, 1996.
13. Perez-Pinzon MA, Maier CM, Yoon EJ, Sun GH, Giffard RG, Steinberg GK. Correlation of CGS 19755 neuroprotection against in vitro excitotoxicity and focal cerebral ischemia. J Cereb Blood Flow Metab 1995; 15: 867-76.
14. Peruche B, Ahlemeyer B, Brungs H, Krieglstein J. Cultured neurons for testing antihypoxic drug effects. J Pharmacol Meth 1990; 23: 63-77.
15. Wallum E. Studies of neurotoxicity in cellular models. In Castell JV, Gômez-Lechôn MJ, eds. In vitro alternatives to animal pharmacotoxicology. Madrid: Farmaindustria; 1992. p. 205-37.
16. Goldberg AM. Mechanisms of neurotoxicity as studied in tissue culture systems. Toxicology 1980; 17: 201-8.
17. Maroto R, de la Fuente MT, Artalejo AR, Abad F, Lopez MG, GarciaSancho J, et al. Effects of calcium antagonists on chromaffin cell death and cytosolic calcium oscillations induced by veratridine. Eur J Pharmacol (Environ Toxicol Pharmacol Section) 1994; 270: 331-9.
18. Abad F, Maroto R, Lôpez MG, Sanchez-Garcia P, Garcia AG. Pharmacological protection against the cytotoxicity induced by 6-hydroxydopamine in chromaffin cells. Eur J Pharmacol (Environ Toxicol Pharmacol Section) 1995; 293: 55-64.
19. Maroto R, de la Fuente MT, Zapater P, Abad F, Esquerro E, Garcia AG. Effects of w-conotoxin MVIIC on veratridine-induced cytotoxicity and cytosolic Ca:oscillations. Brain Res 1996; 714: 209-14.
20. Pizzi M, Consolandi O, Memo M, Spano P. N-methyl-D-aspartate neurotoxicity in hippocampal slices: Protection by aniracetam. Eur J Pharmacol 1995; 275: 311-4.
21. Zucco F. Use of continuous cell lines for lexicological studies. In Castell JV, Gômez-Lechôn MJ, eds. In vitro alternatives to animal pharmaco-toxicology. Madrid: Farmaindustria; 1992. p. 43-68.
22. Choi DW, Goldberg MP, Monyer H, Weiss JH. Assessment of protective agents in primary central neuronal cell culture. In Ginsberg MD, Dietrich WD, eds. Cerebrovascular diseases. New York: Raven Press; 1989. p. 127-33.
23. Heller A, Won L, Heller B, Hoffmann PC. Examination of developmental neurotoxicity by the use of tissue culture model systems. Clin Exp Pharmacol Physio! 1995; 22: 375-8.
24. Slikker W, Gaylor DW. Risk assessment strategies for neuroprotective agents. Ann N Y Acad Sci 1995; 765: 198-208.
25. Ginsberg MD, Busto R. Rodent models of cerebral ischemia. Stroke 1989; 20: 1627-42.
26. Clifton GL, Taft WC, Blair RE, Choi SC, Delorenzo RJ. Conditions for pharmacologie evaluation in the gerbil model of forebrain ischemia. Stroke 1989; 20: 1545-52.
27. Choi DW. Cerebral hypoxia: Some new approaches and unanswered questions. J Neurosci 1990; 10: 2493-501.
28. Meldrum B, Garthwaite. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990; 11: 379-87.
29. Sofromiew MV, Svendsen CN, Cooper JD, Staley K. Experimental models of neuronal degeneration and Alzheimer's disease. Proceedings of the Symposium on Neurodegeneration and Neuroprotection. 20-21 Diciembre 1990. London: Scrip Reports; 1991. p. 10-6.
30. Monyer H, Goldberg MP, Choi DW. Glucose deprivation neuronal injury in cortical culture. Brain Res 1989; 483: 347-54.
31. Choi DW, Koh JY, Peters S. Pharmacology of glutamate neurotoxicity in cortical cell culture:.Attenuation by NMDA antanonists. J Neurosci 1988; 8: 185-96.
32. Pauwels PJ, van Assouw HP, Peelers L, Leysen JE. Neurotoxic action of veratridine in rat brain neuronal cultures: Mechanism of neuroprotection by Caantagonists nonselective for slow Ca channels. J Pharmacol Exp Ther 1990; 255: 117-22.
33. Hall ED, McCall JM, Chase RL, Yonkers PA, Braughler JM. A nonglucocorticoid steroid analog of methylprednisolone duplicates its highdose pharmacology in models of central nervous system trauma and neuronal membrane damage. J Pharmacol Exp Ther 1987; 242: 137-42.
34. Hall ED, Braughler JM, Yonkers PA, et al. U-785I7F: A potent inhibitor of lipid peroxidation with activity in experimental brain injury and ischemia. J Pharmacol Exp Ther 1991; 258: 688-94.
35. Jonsson G. Chemical neurotoxins as denervation tools in neurobiology. Ann Rev Neurosci 1980; 3: 169-87.
36. Bhuyan BK, Loughman BE, Fraser TJ, Day KJ. Comparison of different methods of determining cell viability after exposure to cytotoxic compounds. Exp Cell Res 1976; 97: 275-80.
37. Castell JV, Gomez-Lechôn MJ. The in vitro evaluation of the potential risk of hepatotoxicity of drugs. In Castell JV, Gömez-Lechön MJ, eds. In vitro alternatives to animal pharmaco-toxicology. Madrid: Farmaindustria; 1992. p. 179-204.
38. Nieminen AL, Gores GJ, Bond JM, Imberti R, Herman B, Lemasters JL. A novel cytotoxicity screening assay using a multiwcll fluorescence scanner. Toxicol Appl Pharmacol 1992; 115: 147-55.
39. Borges R, Sala F, Garcia AG. Continuous monitoring of catecholamine release from perfused cat adrenals. J Neurosci Meth 1986; 16: 389-400.
40. Balazs R, Jorgensen OS, Hack N. N-methyl-D-aspartate promotes the survival of cerebellar granule cells in culture. Ncuroscience 1988; 27: 437-51.
41. Manthorpe M, Fagnani R, Skaper SD, Varon S. An automated colorimctric microassay for neuronotrophic factors. Dev Brain Res 1986; 25: 191-8.
42. Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 1990; 13: 171-82.
43. Ramnath RR, Strange K, Rosenberg PA. Neuronal injury evoked by depolarizing agents in rat cortical cultures. Neuroscience 1992; 51: 931-9.
44. Simon RP, Swan JH. Griffiths T, Meldrum BS. Blockade of N-methyl-D-aspartate receptors may protect acainst ischémie damace in the brain. Science 1984; 226: 850-2.
45. Rich, Hollowell JP. Flunarizine protects neurons from death after axotomy or NGF deprivation. Science 1990; 248: 1419-21.
46. Hall ED, Braughler JM. Central nervous system trauma and stroke: II. Physiological and pharmacological evidence for involvement of oxygen radicals and lipid peroxidation. Free Radical Biol Med 1989; 6: 303-13.
47. Arienti G, Corazzi L, Mastrofini P, Montanini I, Tirillini B, Porcellati G. Involvement of CDP-choline in phospholipid metabolism of brain tissue in vitro. Ital J Biochem 1979; 28: 39-45.
48. Secades JJ, Frontera G. CDP-colina: revision farmacolouica y clinica. Meth Find ExpClin Pharmacol 1995; 17 (Supl 1): 1-56.
49. Horrocks LA, Dorman RV, Porcellati G. Fatty acids and phospholipids in brain during ischemia. Excerpta Med 1984; 654: 211-22.
50. Mykita S, Golly F, Dreyfus H, Frcysz L, Massarelli R. Effect of CDP-choline on hypocapnic neurons in culture. J Neurochem 1986; 47: 223-31.